Gilead adds an IL-23 program from China's PepStar to its IBD pipeline
- Gilead has picked up a new inflammatory disease program from China's PepStar Therapeutics.
- It is meant to pair with Gilead's Phase 2 inflammatory bowel disease asset emvistegrast.
- BioSpace's headline cites a $1.3 billion figure; the modality and the financial breakdown were not available from the feed text.
💡 Points
Putting an IL-23 asset next to emvistegrast reads as a bid for combination or sequencing in IBD, where single-pathway drugs plateau. Another China-originated I&I license also fits the trend of Western pharma buying early. Until the payment split is clear, the headline figure tells us little about how much Gilead is actually committing.
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar ↗